The company has purchased a minority stake in the German company iRT Systems, in order to improve its quality assurance (QA) offering to clinics and hospitals.
For the past six years, iRT Systems has developed the Integral Quality Monitor (IQM) system in cooperation with Princess Margaret Cancer Centre, part of the University Health Network (UHN), in Toronto, Canada. IQM is the first verification system available on the market that monitors the delivered treatment while comparing it to the planned treatment in real time. IQM is integrated into the treatment workflow, acquiring high quality data automatically without user interaction, states the company in its press release.
“Elekta relentlessly pursues the advancement of treatment quality assurance – through innovation, collaboration or procurement – by elevating quality control at all stages of the workflow,” said Maurits Wolleswinkel, Head of Portfolio and Chief Strategy Officer at Elekta. “With our stake in iRT, we can help ensure that all oncology departments can do so, more accurately, efficiently and reliably, by using IQM.”
IQM has CE mark, FDA 510(k) clearance as well as regulatory approvals in Canada and Australia and other markets.
